Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telomelysin (OBP-301) in Hepatocellular Carcinoma
NCT02293850Phase 1Unknown
- Sponsor
- Oncolys BioPharma Inc.
- Start
- Oct 2014
- Primary completion
- Apr 2019
- Modality
- Oncolytic Viruses
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of suratadenoturev in hepatocellular carcinoma (HCC), sponsored by Oncolys BioPharma Inc. Primary endpoint: Evaluation of safety parameters at 14 weeks. Status: unknown.
02
Drugs
suratadenoturev
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02293850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02293850.